Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.

Abstract:

OBJECTIVE:To examine the effect of postsurgical surveillance on survival of patients with FIGO stage I/II endometrial adenocarcinoma. METHODS:We examined the records of 354 patients who underwent primary surgical therapy for FIGO stage I/II endometrial adenocarcinoma. In patients who developed recurrent disease, we determined whether symptoms or signs of disease were present at recurrence and whether there was evidence of disease on Pap smear or chest radiograph. RESULTS:Among the 354 patients in this study, 44 (12%) developed recurrent disease. Sites of recurrence included 12 (27%) isolated vaginal, 12 (27%) pelvic with vagina or abdomen, 4 (10%) isolated lung, 13 (29%) pelvic/abdominal with other distant sites, and 3 (7%) other distant sites. At diagnosis of recurrence 61% of patients had symptoms related to their cancer, 68% had physical exam findings suggestive of recurrence, and 84% had symptoms and/or signs. Findings consistent with recurrent cancer were detected by Pap smear in 25% and on chest radiograph in 20%. Among the 44 patients who developed recurrent disease, 8 (18%) remain alive without evidence of disease, including 6/12 (50%) with isolated vaginal disease and 2/34 (6%) with other patterns of recurrent disease (P = 0.01). Among the 12 patients with isolated vaginal recurrence, 1/3 (33%) in whom recurrent disease was diagnosed by Pap smear alone was salvaged compared to 5/9 (56%) who had symptoms or signs of vaginal recurrence. None of the three patients in whom an abnormal chest radiograph was the only evidence of recurrence survived. CONCLUSIONS:Because of the low recurrence rate of FIGO stage I/II endometrial cancer and the paucity of effective second-line treatment, surveillance Pap smears and chest radiographs appear to have little impact on survival. Although few asymptomatic potentially curable recurrences were detected due to surveillance examinations, the value of psychological reassurance associated with a normal examination is difficult to quantitate.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Berchuck A,Anspach C,Evans AC,Soper JT,Rodriguez GC,Dodge R,Robboy S,Clarke-Pearson DL

doi

10.1006/gyno.1995.1262

subject

Has Abstract

pub_date

1995-10-01 00:00:00

pages

20-4

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(85)71262-0

journal_volume

59

pub_type

临床试验,杂志文章
  • Malignant mixed mullerian tumor arising in extragenital endometriosis: report of a case and review of the literature.

    abstract::A primary malignant mixed Mullerian tumor (MMMT) was found in the wall of the rectum of a 67-year-old female. The uterus, fallopian tubes, and ovaries had been previously excised for benign disease. The tumor was associated with foci of benign endometriosis. A literature review of extragenital MMMTs indicates that the...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90228-3

    authors: Chumas JC,Thanning L,Mann WJ

    更新日期:1986-02-01 00:00:00

  • Gynecologic cancer clues to Lynch syndrome II diagnosis: a family report.

    abstract::Lynch syndrome II was diagnosed when two sisters manifested early-onset synchronous carcinomas of the ovary and endometrium and a third sister was found to have Duke's A carcinoma of the cecum. A detailed cancer family history indicated paternal transmission of the deleterious genotype. The pattern of carcinoma of the...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90040-p

    authors: Lynch HT,Cavalieri RJ,Lynch JF,Casey MJ

    更新日期:1992-02-01 00:00:00

  • A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

    abstract:OBJECTIVE:The mTOR inhibitor, temsirolimus, has clinical activity in the treatment of gynecologic malignancies, particularly endometrial cancer. We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus. METHODS:Women with a history of advanced or recurrent gynecologic mal...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.02.022

    authors: Temkin SM,Yamada SD,Fleming GF

    更新日期:2010-06-01 00:00:00

  • The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum.

    abstract::cis-Platinum is a chemotherapeutic agent with benefits often limited by the severe gastrointestinal reactions it produces in nearly all patients. Persistent anorexia, nausea, and vomiting may continue for days after therapy and are poorly controlled by conventional antiemetics. Patients at times refuse continuation of...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(85)90268-9

    authors: Benrubi GI,Norvell M,Nuss RC,Robinson H

    更新日期:1985-07-01 00:00:00

  • The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data.

    abstract:OBJECTIVE:This article critically reviews the literature on the association between endometriosis and gynecological cancers and breast cancer, based on epidemiologic data. METHODS:Literature review of the English language literature based on searching in the MEDLINE (PubMed) database and additional collection of repor...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2011.06.017

    authors: Munksgaard PS,Blaakaer J

    更新日期:2011-10-01 00:00:00

  • Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer.

    abstract:OBJECTIVE:The purpose was to explore whether health education on symptoms of ovarian cancer would aid in early detection, by examining the relationship between symptoms, coping strategies, and timing of presentation in patients with newly diagnosed ovarian cancer. METHODS:Eighty women were included. A questionnaire co...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00394-9

    authors: Chan YM,Ng TY,Lee PW,Ngan HY,Wong LC

    更新日期:2003-09-01 00:00:00

  • Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

    abstract:OBJECTIVE:Proliferative activity (PA) may be an indicator of a neoplasm's malignant potential, and it has been described as a prognostic factor in different malignant tumors. It was our aim to study the prognostic significance of PA defined by Ki-S5 and Ki-S2 immunohistochemical staining in a large homogeneously treate...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.01.037

    authors: Kommoss S,du Bois A,Schmidt D,Parwaresch R,Pfisterer J,Kommoss F

    更新日期:2006-10-01 00:00:00

  • The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system.

    abstract:OBJECTIVE:The 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer changed from a clinical system to a clinical/pathologic/radiologic system with stages IIIC1 and IIIC2 indicating positive pelvic and para-aortic lymph nodes, respectively. We evaluated the National Cancer ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.10.025

    authors: McComas KN,Torgeson AM,Ager BJ,Hellekson C,Burt LM,Maurer KA,Werner TL,Gaffney DK

    更新日期:2020-01-01 00:00:00

  • Integrated analysis of HPV-mediated immune alterations in cervical cancer.

    abstract:OBJECTIVE:Human papillomavirus (HPV) infection is the primary cause of cervical cancer. HPV-mediated immune alterations are known to play crucial roles in determining viral persistence and host cell transformation. We sought to thoroughly understand HPV-directed immune alterations in cervical cancer by exploring public...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.01.031

    authors: Chen L,Luan S,Xia B,Liu Y,Gao Y,Yu H,Mu Q,Zhang P,Zhang W,Zhang S,Wei G,Yang M,Li K

    更新日期:2018-05-01 00:00:00

  • Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2).

    abstract:OBJECTIVE:Bilateral oophorectomy (BOE) is often recommended in order to prevent cancer at hysterectomy for non-malignant diseases and when familial risk of ovarian and breast cancer has been identified. Surgical menopause increases the risk of cardiovascular mortality, however, the intervening mechanisms are not clear....

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.02.025

    authors: Dørum A,Tonstad S,Liavaag AH,Michelsen TM,Hildrum B,Dahl AA

    更新日期:2008-06-01 00:00:00

  • Pre-diagnosis body mass index, physical activity and ovarian cancer mortality.

    abstract:BACKGROUND:Ovarian cancer is the deadliest gynecologic malignancy, yet the effects on survival of modifiable pre-diagnosis lifestyle factors, such as obesity and physical activity, remain largely unexplored. Our objective was to evaluate the effect of pre-diagnosis BMI and physical activity on ovarian cancer mortality ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.07.025

    authors: Zamorano AS,Hagemann AR,Morrison L,Lee JA,Liao LM,Brinton LA,Park Y,Toriola AT

    更新日期:2019-10-01 00:00:00

  • Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

    abstract:OBJECTIVE:Australia's HPV vaccination and HPV-based cervical screening programs are changing the landscape in cervical cancer prevention. We aim to identify areas which can make the biggest further impact on cervical cancer burden. This protocol describes the first stage of a program of work called Pathways-Cervix that...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.12.019

    authors: Velentzis LS,Smith MA,Simms KT,Lew JB,Hall M,Hughes S,Yuill S,Killen J,Keane A,Butler K,Darlington-Brown J,Hui H,Brotherton JML,Skinner R,Brand A,Roeske L,Heley S,Carter J,Bateson D,Frazer I,Garland SM,Guy R,H

    更新日期:2019-03-01 00:00:00

  • Bone metastasis from cervix cancer.

    abstract::Among 713 patients followed after treatment for cancer of the uterine cervix, 48 (6.6%) had a metastasis to the bone. The rates of metastasis in each of the four clinical stages were 11/273 (4.0%) in stage I, 16/243 (6.6%) in stage II, 13/162 (8.0%) in stage III, and 8/35 (22.9%) in stage IV, respectively. The most fr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90853-6

    authors: Matsuyama T,Tsukamoto N,Imachi M,Nakano H

    更新日期:1989-01-01 00:00:00

  • Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.

    abstract:OBJECTIVE:To compare clinical outcomes of patients diagnosed with low-risk gestational trophoblastic neoplasia (GTN) receiving intramuscular methotrexate 50 mg total dose/day versus 1 mg/kg/day in a 8-day methotrexate/folinic acid (MTX/FA) regimen. METHODS:This retrospective, multicenter study included 176 patients: 9...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2018.09.025

    authors: Mangili G,Cioffi R,Danese S,Frigerio L,Ferrandina G,Cormio G,Rabaiotti E,Scarfone G,Gadducci A,Bergamini A,Pisano C,Candiani M

    更新日期:2018-12-01 00:00:00

  • The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of response to CDP in lower limb lymphedema (LLL) after pelvic cancer treatment.

    abstract:OBJECTIVE:The aim of this study was to estimate the efficacy of an intensive CDP program, as well as to identify the predictors associated with lymphedema severity and response to CDP in lower limb lymphedema (LLL) after pelvic cancer therapy. METHODS:We performed a retrospective review of post-pelvic cancer LLL patie...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.03.017

    authors: Liao SF,Li SH,Huang HY

    更新日期:2012-06-01 00:00:00

  • Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

    abstract:OBJECTIVE:Previous studies by the Gynecologic Oncology Group have demonstrated a 7% response rate with bolus etoposide as second-line therapy in nonsquamous cell carcinoma of the cervix. Prolonged oral etoposide, which exploits the schedule dependency of this agent, has demonstrated increased activity in squamous carci...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0090-8258(03)00079-9

    authors: Rose PG,Blessing JA,Buller RE,Mannel RS,Webster KD

    更新日期:2003-05-01 00:00:00

  • Regional lymph node recurrence following local excision for microinvasive vulvar carcinoma.

    abstract::A case of microinvasive squamous cell carcinoma of the vulva is reported in which regional lymph node recurrence was noted after excisional therapy. Review of the initial pathology revealed only 0.72 mm of invasion. The results of a literature survey regarding microinvasive vulvar carcinoma are discussed. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90123-6

    authors: Atamdede F,Hoogerland D

    更新日期:1989-07-01 00:00:00

  • Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: prognostic implications of tumor persistence.

    abstract::Twenty-five patients underwent adjunctive extrafascial hysterectomy 14-60 days following completion of external and intracavitary irradiation for bulky carcinoma of the uterine cervix. Review of the operative histopathology and correlation with subsequent patient outcomes suggests that morphologically persistent cance...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(87)90217-4

    authors: Russell AH,Burt AR,Ek M,Russell KJ,Cain JM,Greer BE,Tamimi HK,Figge DC

    更新日期:1987-10-01 00:00:00

  • Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment.

    abstract:OBJECTIVE:This study's objective was to quantify the impact (utility) of common complications of early cervical cancer treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers. METHODS:30 survivors of early cervical cancer identified from our Tumor Registry and 1...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.10.033

    authors: Einstein MH,Rash JK,Chappell RJ,Swietlik JM,Hollenberg JP,Connor JP

    更新日期:2012-04-01 00:00:00

  • Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women.

    abstract:OBJECTIVES:To compare survival of Hispanic white (HW) and non-Hispanic white (NHW) women with type II endometrial adenocarcinoma (EC). METHODS:Patients with serous, clear cell or grade 3 endometrioid EC were identified from the Surveillance, Epidemiology, and End Results (SEER) program 1988-2009 and were divided into ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.03.562

    authors: Mahdi H,Hou H,Kowk LL,Moslemi-Kebria M,Michener C

    更新日期:2014-06-01 00:00:00

  • The Patient Protection and Affordable Care Act: what every provider of gynecologic oncology care should know.

    abstract::The Patient Protection and Affordable Care Act (ACA) was signed into law by President Barack Obama in 2010. While initial implementation of the law began shortly thereafter, the full implementation will take place over the next few years. With respect to cancer care, the act was intended to make care more accessible, ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2013.02.036

    authors: Duska LR,Engelhard CL

    更新日期:2013-06-01 00:00:00

  • Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.

    abstract:OBJECTIVE:The objective of this study was to determine the efficacy of a low-dose oral granisetron plus intravenous dexamethasone prophylactic antiemetic regimen in patients receiving carboplatin-based chemotherapy. PATIENTS AND METHODS:Patients with gynecologic malignancies being treated with either single-agent carb...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1998.5168

    authors: Markman M,Kennedy A,Webster K,Kulp B,Peterson G,Belinson J

    更新日期:1998-10-01 00:00:00

  • Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?

    abstract:OBJECTIVE:The objective was to describe trends over time in key factors surrounding end-of-life care on a gynecologic oncology service at a tertiary cancer center. METHODS:Patients with gynecologic cancers who were hospitalized and died at our institution between 1992 and 1997 were identified using institutional datab...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6616

    authors: Dalrymple JL,Levenback C,Wolf JK,Bodurka DC,Garcia M,Gershenson DM

    更新日期:2002-05-01 00:00:00

  • Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?

    abstract::As gynecologic surgeons garnered a better understanding of various clinical-pathological prognostic factors, there evolved a number of modifications in the surgical approach allowing for more individualized therapy with less morbidity, while still retaining the curative potential of the radical vulvectomy operation. T...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2009.01.004

    authors: Moore DH

    更新日期:2009-06-01 00:00:00

  • 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.

    abstract::Twenty-nine patients with recurrent advanced stage ovarian cancer were treated with 5-fluorouracil (5-FU) and leucovorin by intravenous bolus on 5 consecutive days, repeated every 3 weeks. Twenty-one of these patients had experienced disease progression while receiving a cisplatin- or carboplatin-based regimen. There ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90226-9

    authors: Reed E,Jacob J,Ozols RF,Young RC,Allegra C

    更新日期:1992-09-01 00:00:00

  • Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.

    abstract::Thirty-eight patients with advanced or recurrent carcinoma of the endometrium who had received no prior chemotherapy were placed on study by the Gynecologic Oncology Group. One was deemed histologically ineligible. Three patients had insufficient trials to evaluate response. Of the remaining 34 who received hexamethyl...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(88)80028-3

    authors: Thigpen JT,Blessing JA,Ball H,Hanjani P,Manetta A,Homesley H

    更新日期:1988-11-01 00:00:00

  • Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.

    abstract:OBJECTIVES:To evaluate the prevalence and associated prognostic indicators in patients with vulvar carcinoma with and without evidence of perineural invasion (PNI). METHODS:A retrospective review identified 421 patients with invasive vulvar carcinoma evaluated at a single institution between 1993 and 2011. Medical rec...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.10.035

    authors: Salcedo MP,Sood AK,Dos Reis R,Ramalingam P,Chen C,Frumovitz M,Jhingran A,Pitcher B,Ramirez PT,Schmeler KM

    更新日期:2019-01-01 00:00:00

  • Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.

    abstract:OBJECTIVE:Therapy related acute myeloid leukemia (t-AML) is a potential late complication of cytotoxic therapy, and it is of particular concern in the treatment of patients with epithelial ovarian carcinoma (EOC) exposed to multiple courses of chemotherapy during the course of their disease. This study examines the inc...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.07.097

    authors: Vay A,Kumar S,Seward S,Semaan A,Schiffer CA,Munkarah AR,Morris RT

    更新日期:2011-12-01 00:00:00

  • Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome.

    abstract:OBJECTIVE:To update the demographic data, treatment details and outcomes for GTN patients with brain metastases managed with the modern treatment protocols at the UK centre for gestational trophoblast neoplasia at Charing Cross Hospital in London. METHODS:The hospital database and pharmacy records were reviewed to ide...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.01.530

    authors: Savage P,Kelpanides I,Tuthill M,Short D,Seckl MJ

    更新日期:2015-04-01 00:00:00

  • Treatment of cervical intraepithelial neoplasia with the carbon dioxide laser.

    abstract::Between 1978 and 1983, one hundred and forty-six patients with CIN I-III were treated with the carbon dioxide laser and 129 have been followed for 6 to 58 months. The remission rate was 92.2% after one treatment and 98.4% after two treatments. All persistent lesions were detected within 8 weeks after treatment. After ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90271-9

    authors: Tsukamoto N

    更新日期:1985-07-01 00:00:00